The gene synthesis market size was exhibited at USD 2.36 billion in 2024 and is projected to hit around USD 10.59 billion by 2034, growing at a CAGR of 16.2% during the forecast period 2025 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 2.74 Billion |
| Market Size by 2034 | USD 10.59 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 16.2% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Method, Service, Application, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | GenScript; GENEWIZ; Boster Biological Technology; Twist Bioscience; ProteoGenix, Inc.; Biomatik; ProMab Biotechnologies, Inc.; Thermo Fisher Scientific, Inc.; Integrated DNA Technologies, Inc.; OriGene Technologies, Inc. |
The growth of the market is attributed to factors such as favorable government policies relating to synthetic biology. Investors have been more focused on synthetic biology research during the past few years. Approximately USD 8.0 billion in governmental and commercial funding was allocated to the synthetic biology sector in 2020. The COVID-19 outbreak has benefited the gene synthesis market by creating significant growth opportunities. Researchers are exploring untapped possibilities in the gene synthesis field, which is helping to boost market growth in terms of revenue generation. For instance, researchers at the National Institute of Standards and Technology have developed synthetic SARS-CoV-2 gene fragments to assist researchers to develop accurate and reliable diagnostic tests for the disease.
Synthetic DNA technological advancements are getting significant traction as a viable method to address concerns associated with the increasing number of emerging viruses and the potential threats of the next global pandemic. The SARS-CoV-2 pandemic along with pandemics involving other novel diseases in the near future can be rapidly addressed with the help of this promising technique to quickly replicate and analyze genes of interest.
Targeted therapy has gained significant interest from the biotechnology and pharmaceutical industry and researchers. It has become an important technique of disease management. Targeted therapy in combination with immunotherapy and chemotherapy is anticipated to witness significant growth in the coming years. This would open up lucrative opportunities for both established and emerging players in the gene synthesis market.
The lack of skilled professionals in the field of gene synthesis and biotechnology is one of the main factors which could hinder the market growth, as the companies operating in this market would require trained and experienced staff at their facilities. Therefore, companies are entering into several strategic collaborations with universities to offer staff online workshops, on-site training, and sponsored projects to develop the right professionals. This would further help to drive the gene synthesis market growth.
Solid-phase synthesis dominated the gene synthesis market in 2024 owing to the increasing adoption rate during the past few years. The segment held around 35.87% of the revenue share in 2024. This is a prominent technology for applications in several fields and for various research purposes, since it may be used to create modified & canonical polymers of nucleic acids, specifically RNA or DNA.
Most companies currently offering commercial services for gene synthesis utilize a solid-phase synthesis process, using various synthesis platforms made available by companies such as Agilent technology, Blue Heron Biotech, and Sloning BioTechnology, among others.
The PCR-based enzyme segment is expected to register the fastest CAGR during the forecast period. Certain factors such as its precision, ease of use, and reasonably priced technology are the factors estimated to accelerate segment growth by 2030. It is an effective method to produce the A+T-rich malaria genome.
Moreover, PCR-based gene synthesis provides a simple solution to the issue of producing significant amounts of labeled protein for NMR spectroscopy, when the gene encoding the protein is difficult or unavailable to express effectively. Thus, the aforementioned applications of this technique are contributing to segment growth.
The antibody DNA synthesis segment held a 60.90% share of the market in 2024. The presence of several market players offering services for antibody DNA synthesis has contributed to the gene synthesis market dominance in 2024. Companies are providing services to research institutions and biotech/ pharma companies to allow cloning and synthesis of antibody chain sequences into any vector.
Viral gene synthesis is projected to witness the fastest growth rate owing to the growing virus vector-related R&D activities. Furthermore, companies are involved in the synthesis of all structural and non-structural gene fragments or protein genes of the SARS-CoV-2. In February 2024, Eleven Therapeutics and Twist Bioscience Corporation developed a replicon tool, which can be used to examine viral genome replication and antiviral drug screening, along with therapeutic & vaccine development.
The gene & cell therapy development segment dominated the gene synthesis market by holding a 35.53% share of the revenue in 2024. This is anticipated to expand the advanced therapies pipeline for the treatment of chronic diseases. These therapies are gaining significant acceptance among therapy developers due to their efficiency in treating diseases that were not treatable using the traditional mode of treatment.
Several initiatives have been undertaken by biotechnology and pharmaceutical companies to promote cell and gene therapy treatments. In January 2024, Century Therapeutics entered into a collaboration with Bristol Myers Squibb Company to develop iPSC-derived allogeneic cell therapies.
Disease diagnosis is anticipated to witness the fastest growth rate in the coming years owing to the growing disease burden worldwide and a rising need for enhancement in medical diagnostics. Synthetic biology provides bio-molecular engineering strategies that can go beyond the limitations of traditional antibody-based diagnostics platforms, which are usually slow, expensive, and not appropriate for the testing of emerging pathogens or rare diseases.
Moreover, the increasing adoption of advanced techniques for driving scientific advancements, such as the production of designer cells that can employ synthetic gene circuits for surveying disease biomarkers and aiding in disease diagnosis, is also contributing to the segment’s growth.
Academic and government research institutes dominated the gene synthesis market in 2024 in terms of revenue share, owing to the increasing usage of gene synthesis services in research settings. In 2024, the segment held around 55.0% share of revenue globally. The research institutes are entering into collaborations with service providers to speed up their research programs that require the characterization and synthesis of gene fragments.
Biotechnology and pharmaceutical companies are projected to witness significant growth in the coming years. Key players are also focusing on the development and launch of new platforms that can enhance the gene synthesis process. For instance, in August 2020, Codex DNA launched BioXp 3250 system for synthetic biology workflow. This platform aims to accelerate the development of new biologics and vaccines. It allows researchers to generate large DNA fragments of up to 7kb at high speed without compromising accuracy. These factors would further contribute to the segment’s growth.
North America held the largest revenue share in 2024. This can be attributed to the presence of several key market players offering gene synthesis services, increasing interest of major biotechnology & pharmaceutical companies in gene & cell therapy development, the expanding field of synthetic biology in the region, and increasing interest in gene synthesis in the molecular biology arena.
Furthermore, the presence of a high number of contract research organizations (CROs) providing gene synthesis services is expected to increase revenue in the region. For instance, GenScript has established a significant presence across the North American region. It offers a broad range of services, including antibody drug development services and custom gene synthesis services
Asia Pacific is projected to witness the fastest growth rate during the forecast period due to increasing research activities for the development of effective therapeutics, coupled with increasing interest in synthetic biology research. In addition, there is a growing incidence of diseases due to lifestyle changes. Improving healthcare infrastructure, entry of large biotechnology organizations, and growing R&D activities are also expected to contribute to market growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the gene synthesis market
By Method
By Services
By Application
By End-use
By Regional
Chapter 1 Gene Synthesis Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: CAGR Calculation
1.8 Regional Market: CAGR Calculation
1.9 List Of Secondary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.11 List of Abbreviations
Chapter 2 Gene Synthesis Market: Executive Summary
2.1 Gene Synthesis Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Gene Synthesis Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rising investment in synthetic biology market
3.3.1.2 Advent of enzymatic DNA synthesis process
3.3.1.3 Technological advancements in the DNA synthesis platforms
3.3.1.4 Declining price of DNA synthesis & sequencing
3.3.2 Market restraint Analysis
3.3.2.1 Lack of skilled professionals
3.3.2.2 Misuse of gene synthesis
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Gene Synthesis Market: Competitive Landscape
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Gene Synthesis Market: Method Business Analysis
5.1 Gene Synthesis Market: Method Movement Analysis
5.2 Solid-phase Synthesis
5.2.1 Solid-phase Synthesis market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Chip-based Synthesis
5.3.1 Chip-based Synthesis market estimates and forecast, 2018 - 2030 (USD Million)
5.4 PCR-based Enzyme Synthesis
5.4.1 PCR-based Enzyme Synthesis market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6 Gene Synthesis Market: Services Business Analysis
6.1 Gene Synthesis Market: Services Movement Analysis
6.2 Antibody DNA Synthesis
6.2.1 Antibody DNA Synthesis market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Viral DNA Synthesis
6.3.1 Viral DNA Synthesis market estimates and forecast, 2018 - 2030 (USD Million)
6.4 Others
6.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 Gene Synthesis Market: Application Business Analysis
7.1 Gene Synthesis Market: Application Movement Analysis
7.2 Gene & Cell Therapy Development
7.2.1 Gene & Cell Therapy Development market estimates and forecast, 2018 - 2030 (USD Million)
7.3 Vaccine Development
7.3.1 Vaccine Development market estimates and forecast, 2018 - 2030 (USD Million)
7.4 Disease Diagnosis
7.4.1 Disease Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
7.5 Others
7.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 Gene Synthesis Market: End-use Business Analysis
8.1 Gene Synthesis Market: End-use Movement Analysis
8.2 Biotechnology and Pharmaceutical Companies
8.2.1 Biotechnology and Pharmaceutical Companies market estimates and forecast, 2018 - 2030 (USD Million)
8.3 Academic and Government Research Institutes
8.3.1 Academic And Government Research Institutes market estimates and forecast, 2018 - 2030 (USD Million)
8.4 Contract Research Organizations
8.4.1 Contract Research Organizations market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Gene Synthesis Market: Regional Business Analysis
9.1 North America
9.1.1 Swot Analysis
9.1.1.1 North America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.1.2 U.S.
9.1.2.1 Key Country Dynamics
9.1.2.2 Target Disease Prevalence
9.1.2.3 Competitive Scenario
9.1.2.4 Regulatory Framework
9.1.2.5 Reimbursement Scenario
9.1.2.6 U.S. Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.1.3 CANADA
9.1.3.1 Key Country Dynamics
9.1.3.2 Target Disease Prevalence
9.1.3.3 Competitive Scenario
9.1.3.4 Regulatory Framework
9.1.3.5 Reimbursement Scenario
9.1.3.6 Canada Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2 Europe
9.2.1 SWOT Analysis:
9.2.1.1 Europe Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.2 Germany
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 Germany Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.3 UK
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 UK Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.4 FRANCE
9.2.4.1 Key Country Dynamics
9.2.4.2 Target Disease Prevalence
9.2.4.3 Competitive Scenario
9.2.4.4 Regulatory Framework
9.2.4.5 Reimbursement Scenario
9.2.4.6 France Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.5 Italy
9.2.5.1 Key Country Dynamics
9.2.5.2 Target Disease Prevalence
9.2.5.3 Competitive Scenario
9.2.5.4 Regulatory Framework
9.2.5.5 Reimbursement Scenario
9.2.5.6 Italy Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.6 Spain
9.2.6.1 Key Country Dynamics
9.2.6.2 Target Disease Prevalence
9.2.6.3 Competitive Scenario
9.2.6.4 Regulatory Framework
9.2.6.5 Reimbursement Scenario
9.2.6.6 Spain Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.7 Denmark
9.2.7.1 Key Country Dynamics
9.2.7.2 Target Disease Prevalence
9.2.7.3 Competitive Scenario
9.2.7.4 Regulatory Framework
9.2.7.5 Reimbursement Scenario
9.2.7.6 Denmark Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.8 Sweden
9.2.8.1 Key Country Dynamics
9.2.8.2 Target Disease Prevalence
9.2.8.3 Competitive Scenario
9.2.8.4 Regulatory Framework
9.2.8.5 Reimbursement Scenario
9.2.8.6 Sweden Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.9 Norway
9.2.9.1 Key Country Dynamics
9.2.9.2 Target Disease Prevalence
9.2.9.3 Competitive Scenario
9.2.9.4 Regulatory Framework
9.2.9.5 Reimbursement Scenario
9.2.9.6 Norway Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3 Asia Pacific
9.3.1 Swot Analysi:
9.3.1.1 Key Region Dynamics
9.3.1.2 Asia Pacific Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.2 Japan
9.3.2.1 Target Disease Prevalence
9.3.2.2 Competitive Scenario
9.3.2.3 Regulatory Framework
9.3.2.4 Reimbursement Scenario
9.3.2.5 Japan Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.3 China
9.3.3.1 Target Disease Prevalence
9.3.3.2 Competitive Scenario
9.3.3.3 Regulatory Framework
9.3.3.4 Reimbursement Scenario
9.3.3.5 China Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.4 India
9.3.4.1 Target Disease Prevalence
9.3.4.2 Competitive Scenario
9.3.4.3 Regulatory Framework
9.3.4.4 Reimbursement Scenario
9.3.4.5 India Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.5 South Korea
9.3.5.1 Target Disease Prevalence
9.3.5.2 Competitive Scenario
9.3.5.3 Regulatory Framework
9.3.5.4 Reimbursement Scenario
9.3.5.5 South Korea Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.6 Australia
9.3.6.1 Target Disease Prevalence
9.3.6.2 Competitive Scenario
9.3.6.3 Regulatory Framework
9.3.6.4 Reimbursement Scenario
9.3.6.5 Australia Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.7 Thailand
9.3.7.1 Target Disease Prevalence
9.3.7.2 Competitive Scenario
9.3.7.3 Regulatory Framework
9.3.7.4 Reimbursement Scenario
9.3.7.5 Thailand Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4 Latin America
9.4.1 Swot Analysis:
9.4.2 Key Regional Dynamics
9.4.2.1 Latin America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.3 Brazil
9.4.3.1 Target Disease Prevalence
9.4.3.2 Competitive Scenario
9.4.3.3 Regulatory Framework
9.4.3.4 Reimbursement Scenario
9.4.3.5 Brazil Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.4 Mexico
9.4.4.1 Target Disease Prevalence
9.4.4.2 Competitive Scenario
9.4.4.3 Regulatory Framework
9.4.4.4 Reimbursement Scenario
9.4.4.5 Mexico Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.5 Argentina
9.4.5.1 Target Disease Prevalence
9.4.5.2 Competitive Scenario
9.4.5.3 Regulatory Framework
9.4.5.4 Reimbursement Scenario
9.4.5.5 Argentina Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5 Middle East & Africa (MEA)
9.5.1 SWOT ANALYSIS:
9.5.2 KEY regional DYNAMICS
9.5.2.1 Middle East & Africa Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.3 SOUTH AFRICA
9.5.3.1 Target Disease Prevalence
9.5.3.2 Competitive Scenario
9.5.3.3 Regulatory Framework
9.5.3.4 Reimbursement Scenario
9.5.3.5 south Africail Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.4 Saudi Arabia
9.5.4.1 Target Disease Prevalence
9.5.4.2 Competitive Scenario
9.5.4.3 Regulatory Framework
9.5.4.4 Reimbursement Scenario
9.5.4.5 Saudi Arabia Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.5 UAE
9.5.5.1 Target Disease Prevalence
9.5.5.2 Competitive Scenario
9.5.5.3 Regulatory Framework
9.5.5.4 Reimbursement Scenario
9.5.5.5 UAE Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.6 Kuwait
9.5.6.1 Target Disease Prevalence
9.5.6.2 Competitive Scenario
9.5.6.3 Regulatory Framework
9.5.6.4 Reimbursement Scenario
9.5.6.5 Kuwait Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10 Gene Synthesis Market: Company Profiling
10.1 Company Profiles
10.1.1 GenScript
10.1.1.1 Company overview
10.1.1.2 Financial performance
10.1.1.3 Product benchmarking
10.1.1.4 Strategic initiatives
10.1.2 Brooks Automation, Inc. (GENEWIZ)
10.1.2.1 Company overview
10.1.2.2 Financial performance
10.1.2.3 Product benchmarking
10.1.2.4 Strategic initiatives
10.1.3 Boster Biological Technology
10.1.3.1 Company overview
10.1.3.2 Financial performance
10.1.3.3 Product benchmarking
10.1.3.4 Strategic initiatives
10.1.4 Twist Bioscience
10.1.4.1 Company overview
10.1.4.2 Financial performance
10.1.4.3 Product benchmarking
10.1.4.4 Strategic initiatives
10.1.5 ProteoGenix, Inc.
10.1.5.1 Company overview
10.1.5.2 Financial performance
10.1.5.3 Product benchmarking
10.1.5.4 Strategic initiatives
10.1.6 Biomatik
10.1.6.1 Company overview
10.1.6.2 Financial performance
10.1.6.3 Product benchmarking
10.1.6.4 Strategic initiatives
10.1.7 ProMab Biotechnologies, Inc.
10.1.7.1 Company overview
10.1.7.2 Financial performance
10.1.7.3 Product benchmarking
10.1.7.4 Strategic initiatives
10.1.8 Thermo Fisher Scientific, Inc.
10.1.8.1 Company overview
10.1.8.2 Financial performance
10.1.8.3 Product benchmarking
10.1.8.4 Strategic initiatives
10.1.9 Integrated DNA Technologies, Inc.
10.1.9.1 Company overview
10.1.9.2 Financial performance
10.1.9.3 Product benchmarking
10.1.9.4 Strategic initiatives
10.1.10 OriGene Technologies, Inc.
10.1.10.1 Company overview
10.1.10.2 Financial performance
10.1.10.3 Product benchmarking
10.1.10.4 Strategic initiatives
10.2 List of Other Key Players
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers